Check out these key findings about Revolution Medicines Inc. (RVMD)

Revolution Medicines Inc. (NASDAQ: RVMD) stock jumped 5.44% on Friday to $18.41 against a previous-day closing price of $17.46. With 1.51 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.96 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $18.59 whereas the lowest price it dropped to was $17.03. The 52-week range on RVMD shows that it touched its highest point at $34.16 and its lowest point at $14.08 during that stretch. It currently has a 1-year price target of $30.00.

Top 5 Tech Stocks Every Investor Should Buy Right Now

While finding excellent stocks with the potential for gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Tech Stocks Every Investor Should Buy Right Now", we have identified five tech stocks we believe could appreciate.

Sign up here to get your free report now.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of RVMD was down-trending over the past week, with a drop of -10.98%, but this was down by -19.96% over a month. Three-month performance dropped to -3.96% while six-month performance fell -23.29%. The stock lost -42.07% in the past year, while it has lost -26.86% so far this year. A look at the trailing 12-month EPS for RVMD yields -3.04 with Next year EPS estimates of -3.55. For the next quarter, that number is -0.83. This implies an EPS growth rate of -27.80% for this year and -7.80% for next year.

Float and Shares Shorts:

At present, 87.70 million RVMD shares are outstanding with a float of 86.34 million shares on hand for trading. On Jul 14, 2022, short shares totaled 10.84 million, which was 14.59% higher than short shares on Jun 14, 2022. In addition to Dr. Mark A. Goldsmith Ph.D. as the firm’s CEO, Pres & Chairman, Mr. Jack Anders serves as its Sr. VP of Fin. & Principal Accounting Officer.

Institutional Ownership:

Through their ownership of 89.60% of RVMD’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 33.70% of RVMD, in contrast to 31.36% held by mutual funds. Shares owned by individuals account for 19.59%. As the largest shareholder in RVMD with 7.03% of the stake, Wellington Management Co. LLP holds 6,169,002 shares worth 6,169,002. A second-largest stockholder of RVMD, The Vanguard Group, Inc., holds 5,466,215 shares, controlling over 6.23% of the firm’s shares. Ecor1 Capital LLC is the third largest shareholder in RVMD, holding 4,278,069 shares or 4.88% stake. With a 3.90% stake in RVMD, the BB Biotech AG is the largest stakeholder. A total of 3,421,462 shares are owned by the mutual fund manager. The Vanguard Total Stock Market Index, which owns about 2.46% of RVMD stock, is the second-largest Mutual Fund holder. It holds 2,158,324 shares valued at 44.96 million. SPDR S&P Biotech ETF holds 2.17% of the stake in RVMD, owning 1,906,045 shares worth 39.7 million.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for RVMD since 8 analysts follow the stock currently. There are 5 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 3 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With RVMD analysts setting a high price target of $38.00 and a low target of $20.00, the average target price over the next 12 months is $30.00. Based on these targets, RVMD could surge 106.41% to reach the target high and rise by 8.64% to reach the target low. Reaching the average price target will result in a growth of 62.95% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. RVMD will report FY 2022 earnings on 02/28/2023. Analysts have provided yearly estimates in a range of -$2.91 being high and -$3.56 being low. For RVMD, this leads to a yearly average estimate of -$3.24. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Revolution Medicines Inc. surprised analysts by $0.03 when it reported -$0.82 EPS against a consensus estimate of -$0.85. The surprise factor in the prior quarter was -$0.01. Based on analyst estimates, the high estimate for the next quarter is -$0.71 and the low estimate is -$1.02. The average estimate for the next quarter is thus -$0.83.

Summary of Insider Activity:

Insiders traded RVMD stock several times over the past three months with 6 Buys and 0 Sells. In these transactions, 340,836 shares were bought while 0 shares were sold. The number of buy transactions has increased to 45 while that of sell transactions has risen to 16 over the past year. The total number of shares bought during that period was 1,599,572 while 428,158 shares were sold.

Leave a Comment

Your email address will not be published.